Linked Life Data

1860150

Source:http://linkedlifedata.com/resource/pubmed/id/1860150

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1991-9-5
pubmed:abstractText
The efficacy of standard potency Edmonston-Zagreb (E-Z) measles vaccine was tested in a randomized trial of Black infants in a rural area of South Africa where a measles epidemic was occurring. The following immunization schedules were used: 48 infants aged 4-8.5 months who received 3.9 log 50 infectious units of E-Z vaccine (group A); 48 infants aged 4-8.5 months who received 3.28 log 50 infectious units of Schwarz vaccine (group B); and 28 infants aged greater than 9 months who received 3.28 log 50 infectious units of Schwarz vaccine and served as controls (group C). For infants aged less than 23 weeks who were given either the E-Z or Schwarz vaccine, the number of seropositives was low (28%), irrespective of the pre-vaccination level of measles antibody. There was a higher number of seropositives (68%) among those in the age range greater than 23 weeks to less than 36 weeks who received the E-Z vaccine rather than the Schwarz vaccine (36%). When administered to children aged greater than 36 weeks, the Schwarz vaccine produced a satisfactory, though suboptimal response rate (61%). There was no correlation between seropositivity and pre-vaccination measles antibody status. Use of the standard dose of E-Z vaccine may have been one of the factors for this poor response, and this supports the WHO recommendation that titres higher than the standard potency vaccine are needed if 6-month-old infants are to be successfully immunized against measles.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-120046, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2482000, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2717273, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2879981, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2896828, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2902263, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-2902264, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-3556780, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-3740044, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6135839, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6148572, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6341638, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6348918, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6368888, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-6610499, http://linkedlifedata.com/resource/pubmed/commentcorrection/1860150-7180027
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0042-9686
pubmed:author
pubmed:issnType
Print
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
221-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.
pubmed:affiliation
Department of Paediatrics and Child Health, Faculty of Medicine, University of Natal, Durban, South Africa.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't